Roux-en-Y Gastric Bypass Decreases Pro-inflammatory And Thrombotic Biomarkers In Individuals With Extreme Obesity | 36254
Journal of Obesity & Weight Loss Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity
3rd International Conference and Exhibition on Obesity & Weight Management
Bárbara Dal Molin Netto1, Solange Cravo Bettini2, Ana Paula Grotti Clemente1, Joana Pereira de Carvalho Ferreira1, Katia Boritza2, Sandy de Fátima Souza3, Maria
Emilia Von der Heyde3, Carrie P Earthman4 and Ana Raimunda Dâmaso1
2Hospital de Clínicas, Brazil
3Federal University of Paraná, Brazil
4University of Minnesota, USA
Introduction: The low-grade inflammatory state in obesity leads to insulin resistance and endothelial dysfunction, all of which
promote cardiovascular diseases in individuals with obesity. The purpose of this study was to evaluate the early effects of weight
loss, achieved through bariatric surgery on the inflammatory and prothrombotic states. Additionally, our aim was to identify
the role of hyperleptinemia on the prothrombotic state.
Methods: The sample was composed of 41 extremely obese patients who underwent Roux-en-Y gastric bypass (RYGB).
Anthropometric and clinical data, and biochemical markers of inflammation were collected prior to, as well as 6 months post-
Results: It was found that higher plasminogen activator inhibitor-1 (PAI-1) concentrations among extremely obese individuals
with hyperleptinemia when compared with individuals without hyperleptinemia (p<0.01). In relation to the baseline, postsurgery
BMI was reduced by 12.9 kg/m2, corresponding to 61.73% of excess weight loss. Also, were found decreased significantly in
waist circumference from 126.23 to 101.24 cm, total cholesterol (p<0.01), LDL cholesterol (p=0.02), triglycerides (p<0.01) and
glucose (p=0.01). In regards to pro-inflammatory biomarkers were observed a decrease on the PAI-1 of 55.88±6.02% (p<0.01),
C reactive protein (CPR) 18.8±3.38% (p<0.01), intercellular adhesion molecule-1 (ICAM-1) 89.91±5.7% (p<0.01), leptin
27.86±3.22% (p<0.01) and resistin 69.29±5.8% (p<0.01). Indeed, we also observed significant decreases of the tumor necrosis
factor alpha (TNF-α) and leptin/adiponectin ratio. Anti-inflammatory cytokines adiponectin and interleukin-10 (IL-10) were
significantly increased [170.71±82.50%, p<0.01; 122.71±55.05%, p=0.02]. CRP levels were predictor of ICAM-1 (p=0.04) and
changes in leptin concentrations were predictor decreased PAI-1 levels (p=0.03).
Conclusions: Our findings suggest that obesity per se is associated with a prothrombotic state and patients with hyperleptinemia
have been major cardiovascular risk factors. Hence, the RYGB was effective in early reducing pro-inflammatory and thrombotic
risk in individuals with extreme obesity.
Bárbara Dal Molin Netto completed her graduation in Nutrition from Pontifical Catholic University of Paraná (PUC-PR) in 2006, Curitiba, Brazil. She received a Master’s degree from Federal University of Santa Catarina (UFSC), Florianopolis, Brazil, in the Post-Graduation Program in Clinical Nutrition. Currently, she is a senior doctoral student at Federal University of São Paulo (UNIFESP) in the Post-Graduation Program in Nutrition. Previously, she taught during 2 years at the department of Nutrition at Federal University of Paraná, Curitiba, Brazil. Her expertise includes bariatric surgery, nutritional management of obese individuals and its related chronic illnesses, such as diabetes, hypertension and heart diseases.